We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SISE:BISTTurkiye Sise ve Cam Fabrikalari A.S. Analysis

Data as of 2026-03-15 - not real-time

TRY 41.58

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

SISE trades at roughly half its DCF‑derived fair value of 93.5 TRY, with a trailing PE of 11.8 versus an industry average of 29.1 and a price‑to‑book of 0.51, indicating a substantial valuation discount. Operating margins are slightly negative and free cash flow is currently negative, while the balance sheet carries a high debt load (debt‑to‑equity ~60) that pressures dividend sustainability. The stock shows a bullish macro trend (20‑day SMA above 50‑day SMA and price above the 200‑day SMA) but a bearish MACD histogram and a neutral RSI around 41 suggest short‑term momentum uncertainty. Support sits near 38.9 TRY and resistance near 50.9 TRY, offering upside potential if the price can break the latter level.
Given the low beta (~0.12) and a high volatility of over 38% in the past month, the equity is sensitive to market swings but less correlated with broader indices. The dividend yield of 1.41% is modest and the payout ratio of under 20% is challenged by negative free cash flow, raising questions about long‑term sustainability. Overall, the combination of deep valuation discount, modest growth outlook, and mixed technical signals points to a buy recommendation for medium to long horizons, while a cautious hold is prudent in the near term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram
  • RSI near 40 indicating limited upside
  • Current price near support level

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation gap to DCF fair value
  • Low PE relative to industry peers
  • Bullish trend indicated by moving averages

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Undervalued price-to-book and price-to-sales ratios
  • Potential for operational turnaround and margin improvement
  • Diversified product mix and geographic footprint

Key Metrics & Analysis

Financial Health

Revenue Growth1.70%
Profit Margin4.40%
P/E Ratio11.8
ROE3.52%
ROA-0.01%
Debt/Equity60.14
P/B Ratio0.5
Op. Cash FlowTRY39.7B
Free Cash FlowTRY-54167527424
Industry P/E29.1

Technical Analysis

TrendBullish
RSI41.3
SupportTRY 38.90
ResistanceTRY 50.90
MA 20TRY 44.03
MA 50TRY 43.23
MA 200TRY 38.63
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueTRY 93.54
Target PriceTRY 55.19
Upside/Downside32.73%
GradeUndervalued
TypeBlend
Dividend Yield1.41%

Risk Assessment

Beta0.12
Volatility38.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.